Short Communication

European Journal of Nuclear Medicine

, Volume 23, Issue 6, pp 690-692

First online:

Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma

  • Gerhard GörresAffiliated withInstitute of Nuclear Medicine, Department of Radiology, Kantonsspital, University of Basel
  • , Achim KaimAffiliated withInstitute of Nuclear Medicine, Department of Radiology, Kantonsspital, University of Basel
  • , Andreas OtteAffiliated withInstitute of Nuclear Medicine, Department of Radiology, Kantonsspital, University of Basel
  • , Maik GötzeAffiliated withInstitute of Nuclear Medicine, Department of Radiology, Kantonsspital, University of Basel
  • , Jan Müller-BrandAffiliated withInstitute of Nuclear Medicine, Department of Radiology, Kantonsspital, University of Basel

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

To determine bone mineral density in patients with differentiated thyroid carcinoma receiving thyroxine replacement therapy in suppressive doses, we studied 65 patients (47 women and 18 men; age 25–83 years, mean±SD 52.5±15.4 years). Patients were free of thyroid cancer in clinical and laboratory examinations at the time of the study. Bone mineral density of the lumbar spine and both hips was measured by dual-energy X-ray absorptiometry. There was no decrease in bone density in either 32 postmenopausal or 15 premenopausal women compared with an age- and sex-matched control group, nor was any decrease in bone density found in men. Our data suggest that thyroxine treatment in suppressive doses in patients with differentiated thyroid carcinoma is not a risk factor for the development of osteoporosis.

Key words

Bone mineral density drug effects Thyroxine therapeutic use Thyroid carcinoma drug therapy Osteoporosis epidemiology